The drug company reported last month fourth-quarter earnings of $58.9 million, or 95 cents a share, up from year-earlier earnings of $23.9 million, or 39 cents a share."We believe the newly-launched metereddose pump for Zyclara is starting to gain traction, and with Rx's for the overall imiquimod market continuing to grow, the prospects for significant growth in Zyclara franchise sales are strong in our view," Piper Jaffray analysts wrote in a March 21 report. "We believe Zyclara sales could exceed $125M in 2013. When coupled with steady contribution from Solodyn and likely continued favorable dynamics for the aesthetics business, EPS growth for MRX in 2013 could be well in excess of 20% (on top of >20% growth this year). With strong EPS growth and a 2013 P/E of only ~11x, we continue to believe MRX shares are attractively valued. We reiterate our Overweight rating and $45 PT." Forward Annual Dividend Yield: 1.1% Rated "A (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margins were about the same as they were last year. Medicis Pharmaceutical has weak liquidity. Its Quick Ratio is 0.84, which demonstrates a lack of ability to meet its short-term cash needs. In the fourth quarter, stockholders' net worth remained about the same as it did a year ago. TheStreet Ratings' price target is $46.34. The stock closed Tuesday at $38.50 and has risen 15.79% year to date.
Realty Income The commercial real estate acquirer reported last month fourth-quarter earnings of $34.9 million, or 26 cents a share, up from year-earlier earnings of $31.8 million, or 28 cents a share. "Realty Income has outperformed the REIT Index since June 30, 2011, returning 12.6% compared to the REIT Industry's 4.7%,"Morgan Keegan analysts wrote in a Feb. 15 report. "O currently trades at 18.1x our 2012 FFO per share estimate, the broader equity REIT industry is at 17.4x and closest peer NNN (Market Perform Rated) is at 15.8x. While we believe the net-lease sector offers some defensive value and a relatively attractive dividend, we see no catalyst for share out-performance against the broader REIT Index." Forward Annual Dividend Yield: 4.6% Rated "A+ (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was basically the same from the previous year. In the fourth quarter, stockholders' net worth increased 22.08% from the prior year. TheStreet Ratings' price target is $43.84. The stock closed Tuesday at $38.76 and has risen 10.87% year to date.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts